- By ICR Secretariat
- Posted Wednesday, April 5, 2023
Sanofi, Regeneron surge as Dupixent scores in COPD trial
https://www.biopharmadive.com/news/dupixent-copd-sanofi-regeneron-boreas-study/645800/
- An anti-inflammatory drug from Sanofi and Regeneron succeeded in a Phase 3 clinical trial in chronic obstructive pulmonary disease, giving the medicine, Dupixent, a chance to become the first biologic treatment approved for the condition.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- Future of Intercept’s NASH drug in doubt after FDA panel rejection 30/05/2023 03:56 PM
- 'The Top Line': 2023's biopharma layoffs, plus this week's headlines 30/05/2023 03:55 PM
- How the digital front door benefits clinical trial patients, clinicians and sponsors 30/05/2023 03:53 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org